IQVIA Surges 3.23% as Strategic Partnership with Kexing Biopharm Drives $270M Volume Spike Ranks 395th in Daily Trading Activity

On August 12, 2025, IQVIA (NYSE: IQV) closed with a 3.23% gain, marking a 37.63% surge in trading volume to $270 million. The stock ranked 395th in trading activity for the day, reflecting renewed investor interest driven by a strategic collaboration announced earlier in the week.

Kexing Biopharm, a Chinese biopharmaceutical firm, entered a global partnership with IQVIA to advance its pipeline of innovative drugs and biosimilars. The alliance focuses on accelerating clinical development, regulatory submissions, and market access in Europe and other international markets. IQVIA’s expertise in data-driven clinical trial design and regulatory strategy is expected to enhance Kexing’s global capabilities, aligning with the company’s broader internationalization goals.

The partnership underscores IQVIA’s role in supporting life sciences companies through its advanced analytics and operational infrastructure. Kexing’s CEO highlighted the value of IQVIA’s global insights in optimizing development timelines, while IQVIA’s Asia Pacific president emphasized the strategic fit with Kexing’s rapid overseas expansion. The collaboration aims to leverage IQVIA’s patient data and regulatory knowledge to improve trial efficiency and success rates.

A backtest of a strategy involving the top 500 stocks by daily trading volume from 2022 to 2025 yielded a total profit of $2,300. However, the approach experienced a maximum drawdown of -15.7% in early 2023, illustrating the inherent risks of short-term volume-driven trading strategies in volatile markets.